secwatch.observer — SEC 8-K summary
======================================

Issuer:     TAO Synergies Inc. (TAOX)
CIK:        0001571934
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001104659-22-127597
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synaptogenix Phase 2 trial of Bryostatin-1 fails to meet primary endpoint in advanced Alzheimer's
--------------------------------------------------------------------------------

- Primary endpoint: change in SIB total score at week 28; Bryostatin-1 1.4 pts vs placebo 0.6 pts, not statistically significant.
- Company disappointed, conducting full data review; will provide update on next steps.
- Cash position of ~$38.5M (~$4.00 per share) as of Dec 15, 2022, provides flexibility.
- Trial was NIH-sponsored, double-blind, placebo-controlled for advanced Alzheimer's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1571934/000110465922127597/0001104659-22-127597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1571934/000110465922127597/tm2232868d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-127597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer